ICU Medical (NASDAQ:ICUI) Director Sells $68,977.44 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha Finney sold 378 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the completion of the transaction, the director owned 4,871 shares of the company’s stock, valued at $888,860.08. This represents a 7.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

ICU Medical Stock Performance

Shares of ICUI stock opened at $183.11 on Friday. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of 155.18, a PEG ratio of 2.51 and a beta of 0.74. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. The business’s 50-day moving average price is $155.63 and its 200-day moving average price is $141.67. ICU Medical, Inc. has a 12 month low of $111.42 and a 12 month high of $192.85.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.46. The company had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The firm’s revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts forecast that ICU Medical, Inc. will post 6.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. KeyCorp lifted their price target on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Raymond James Financial restated a “strong-buy” rating and issued a $200.00 price objective on shares of ICU Medical in a report on Friday, August 7th. BTIG Research lifted their target price on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $192.80.

Trending Headlines about ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q2 results beat expectations. ICU Medical reported adjusted earnings of $2.37 per share, well above the $1.91 analyst consensus, while revenue of $547.88 million exceeded estimates of $533.44 million. Revenue increased modestly year over year, and the company maintained fiscal 2026 EPS guidance of $8.60 to $9.00. ICU Medical Q2 2026 Earnings Call Transcript
• Positive Sentiment: Analyst sentiment remains supportive. Following the earnings release, Needham raised its price target to $187, Piper Sandler to $195, and BTIG Research to $200, while maintaining positive ratings. Raymond James also reiterated its strong-buy rating with a $200 target. The consensus rating is “Moderate Buy,” with an average target of $192.80.
• Positive Sentiment: Investor attention remains focused on the earnings call. Analysts’ questions centered on the company’s quarterly performance and outlook, suggesting that the earnings beat and management’s commentary remain the key drivers of current trading interest. The 5 Most Interesting Analyst Questions From ICU Medical’s Q2 Earnings Call
• Neutral Sentiment: Valuation is demanding. ICU Medical trades near its 52-week high at a very elevated forward valuation, making the stock more sensitive to any slowdown in growth or signs that the recent earnings momentum cannot be sustained.
• Negative Sentiment: Several insiders sold shares. Vice President Daniel Woolson sold 5,417 shares for approximately $982,000, COO Christian Voigtlander sold 8,929 shares for about $1.63 million, CIO Ben Sousa sold 2,250 shares for $401,000, and Director Elisha Finney sold 378 shares for roughly $69,000. The transactions reduced their holdings by meaningful percentages and may raise concerns about insider conviction, although such sales can also reflect personal liquidity or diversification. ICU Medical Insider Sales

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in ICU Medical during the second quarter worth approximately $550,250,000. Millennium Management LLC lifted its stake in ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares during the period. Norges Bank bought a new position in shares of ICU Medical during the 4th quarter worth approximately $58,083,000. Reinhart Partners LLC. acquired a new stake in shares of ICU Medical during the 2nd quarter worth approximately $46,148,000. Finally, Thrivent Financial for Lutherans grew its position in shares of ICU Medical by 1,604.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after buying an additional 285,648 shares during the period. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.